Aerie Pharma (AERI) PT Raised to $55 at Stifel Following Analyst Day

October 6, 2016 8:56 AM EDT
Get Alerts AERI Hot Sheet
Price: $42.50 +2.16%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AERI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Stifel analyst Annabel Samimy reiterated a Buy rating and boosted her price target on Aerie Pharma (NASDAQ: AERI) to $55.00 (from $50.00) following the company's analyst day.

Samimy commented, "On the heels of its successful Phase 3 MERCURY readout last month, AERI held an Investor Day to shed additional light into the Roclatan program, commercial positioning for both Rhopressa and Roclatan, and physician reception and future adoption. The Roclatan data reinforce Roclatan’s front-line positioning with efficacy across the broadest spectrum of IOPs and potential to establish a “new low normal” for glaucoma. On Rhopressa, AERI has begun pre-commercialization activities for US launch. In parallel, discussions with Japanese and European health agencies are progressing, but AERI expects to advance clinical/regulatory activities independently while partnership discussions remain ongoing. Separately, AERI continues to engage in preclinical activities intended on expanding Rhopressa’s utility (neuroprotection, disease-modifying, front-of-the-eye sustained delivery) as well as its pipeline optionality (AR-13154/AMD). With a largely de-risked portfolio and multiple ophthalmic activities underway, we believe AERI is well-positioned, and well-financed, to become an important ophthalmic competitor in the coming years. We reiterate our Buy rating and raise our TP to $55."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $39.26 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities


Add Your Comment